CStone’s MEK Inhibitor CS3006 Receives IND Approval in China
SUZHOU, China, July 30, 2018 /PRNewswire/ — CStone Pharmaceuticals (CStone) today announced that its IND application for CS3006, a small-molecule inhibitor of mitogen-activated protein kinase (MEK), has been approved by the China National Drug Administration (CNDA) for clinical trials,…
View more at https://www.prnewswire.com:443/news-releases/cstones-mek-inhibitor-cs3006-receives-ind-approval-in-china-300688262.html
Comments Off on CStone’s MEK Inhibitor CS3006 Receives IND Approval in China